Krittapoom Akrawinthawong
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electrocardiography | 4 | 2018 | 398 | 1.040 |
Why?
|
| Cardiac Pacing, Artificial | 2 | 2018 | 147 | 0.990 |
Why?
|
| Coronary Angiography | 3 | 2014 | 150 | 0.900 |
Why?
|
| Acute Kidney Injury | 2 | 2014 | 74 | 0.790 |
Why?
|
| Contrast Media | 2 | 2014 | 96 | 0.790 |
Why?
|
| Tachycardia, Ventricular | 2 | 2019 | 60 | 0.700 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 2 | 2018 | 96 | 0.690 |
Why?
|
| Pre-Excitation Syndromes | 1 | 2018 | 4 | 0.580 |
Why?
|
| Truncus Arteriosus, Persistent | 1 | 2018 | 4 | 0.570 |
Why?
|
| Heart Rate | 2 | 2019 | 383 | 0.530 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2018 | 173 | 0.490 |
Why?
|
| Atrioventricular Block | 1 | 2015 | 8 | 0.460 |
Why?
|
| Lipocalins | 1 | 2014 | 3 | 0.440 |
Why?
|
| Acute-Phase Proteins | 1 | 2014 | 6 | 0.440 |
Why?
|
| Atrial Fibrillation | 2 | 2017 | 405 | 0.440 |
Why?
|
| Seizures | 1 | 2014 | 50 | 0.420 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 140 | 0.410 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2014 | 47 | 0.410 |
Why?
|
| Ascorbic Acid | 1 | 2013 | 24 | 0.400 |
Why?
|
| Acute Coronary Syndrome | 1 | 2014 | 64 | 0.400 |
Why?
|
| Vitamins | 1 | 2013 | 23 | 0.400 |
Why?
|
| Erythrocytes | 1 | 2014 | 90 | 0.400 |
Why?
|
| Protective Agents | 1 | 2013 | 17 | 0.390 |
Why?
|
| Nitric Oxide | 1 | 2014 | 153 | 0.380 |
Why?
|
| Stroke | 1 | 2015 | 261 | 0.360 |
Why?
|
| Blood Platelets | 1 | 2014 | 207 | 0.360 |
Why?
|
| Iron Chelating Agents | 1 | 2011 | 2 | 0.340 |
Why?
|
| beta-Thalassemia | 1 | 2011 | 2 | 0.340 |
Why?
|
| Iron Overload | 1 | 2011 | 3 | 0.340 |
Why?
|
| Pyridones | 1 | 2011 | 36 | 0.330 |
Why?
|
| Adult | 7 | 2018 | 8130 | 0.260 |
Why?
|
| Humans | 13 | 2019 | 29211 | 0.250 |
Why?
|
| Male | 9 | 2018 | 14126 | 0.250 |
Why?
|
| Catheter Ablation | 2 | 2018 | 223 | 0.230 |
Why?
|
| Female | 7 | 2015 | 15825 | 0.170 |
Why?
|
| Action Potentials | 2 | 2019 | 197 | 0.170 |
Why?
|
| Treatment Outcome | 3 | 2019 | 2442 | 0.170 |
Why?
|
| Middle Aged | 6 | 2017 | 7495 | 0.160 |
Why?
|
| Ablation Techniques | 1 | 2019 | 13 | 0.150 |
Why?
|
| Aortic Valve | 1 | 2018 | 92 | 0.140 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2018 | 64 | 0.140 |
Why?
|
| Ethanol | 1 | 2019 | 127 | 0.130 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 484 | 0.130 |
Why?
|
| Preoperative Care | 1 | 2017 | 81 | 0.120 |
Why?
|
| Risk Assessment | 2 | 2017 | 632 | 0.120 |
Why?
|
| Heart Atria | 1 | 2017 | 177 | 0.120 |
Why?
|
| Evidence-Based Practice | 1 | 2015 | 31 | 0.110 |
Why?
|
| Monitoring, Physiologic | 1 | 2015 | 58 | 0.110 |
Why?
|
| Thrombosis | 1 | 2017 | 155 | 0.110 |
Why?
|
| Risk Factors | 2 | 2018 | 2144 | 0.110 |
Why?
|
| Lipocalin-2 | 1 | 2014 | 6 | 0.110 |
Why?
|
| Asymptomatic Diseases | 1 | 2014 | 17 | 0.110 |
Why?
|
| Creatinine | 1 | 2014 | 60 | 0.110 |
Why?
|
| Glomerular Filtration Rate | 1 | 2014 | 48 | 0.110 |
Why?
|
| Nitric Oxide Donors | 1 | 2014 | 11 | 0.100 |
Why?
|
| Platelet-Rich Plasma | 1 | 2014 | 8 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 250 | 0.100 |
Why?
|
| Hydrazines | 1 | 2014 | 13 | 0.100 |
Why?
|
| Cell Hypoxia | 1 | 2014 | 35 | 0.100 |
Why?
|
| Platelet Activation | 1 | 2014 | 55 | 0.100 |
Why?
|
| Thrombin | 1 | 2014 | 69 | 0.100 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 1033 | 0.100 |
Why?
|
| Flow Cytometry | 1 | 2014 | 292 | 0.100 |
Why?
|
| Oxidation-Reduction | 1 | 2014 | 381 | 0.090 |
Why?
|
| Prognosis | 1 | 2014 | 817 | 0.090 |
Why?
|
| Cohort Studies | 1 | 2014 | 903 | 0.090 |
Why?
|
| Biomarkers | 1 | 2014 | 790 | 0.080 |
Why?
|
| Hemoglobin E | 1 | 2011 | 1 | 0.080 |
Why?
|
| Echocardiography, Doppler | 1 | 2011 | 21 | 0.080 |
Why?
|
| Prospective Studies | 1 | 2014 | 1288 | 0.080 |
Why?
|
| Transfusion Reaction | 1 | 2011 | 10 | 0.080 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2011 | 7 | 0.080 |
Why?
|
| Ferritins | 1 | 2011 | 27 | 0.080 |
Why?
|
| Food Hypersensitivity | 1 | 2010 | 4 | 0.080 |
Why?
|
| Aryldialkylphosphatase | 1 | 2010 | 8 | 0.080 |
Why?
|
| Drug Hypersensitivity | 1 | 2010 | 23 | 0.080 |
Why?
|
| Coronary Disease | 1 | 2010 | 120 | 0.080 |
Why?
|
| Polymorphism, Genetic | 1 | 2010 | 166 | 0.080 |
Why?
|
| Aged | 2 | 2019 | 5648 | 0.070 |
Why?
|
| Oxidative Stress | 1 | 2011 | 692 | 0.060 |
Why?
|
| Young Adult | 1 | 2011 | 2877 | 0.050 |
Why?
|
| Adolescent | 1 | 2011 | 3255 | 0.050 |
Why?
|
| Thailand | 2 | 2010 | 13 | 0.040 |
Why?
|
| Injections, Intra-Arterial | 1 | 2019 | 5 | 0.040 |
Why?
|
| Epicardial Mapping | 1 | 2019 | 8 | 0.040 |
Why?
|
| Coronary Vessels | 1 | 2019 | 154 | 0.030 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2017 | 8 | 0.030 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2017 | 43 | 0.030 |
Why?
|
| Pulmonary Veins | 1 | 2017 | 108 | 0.030 |
Why?
|
| Anaphylaxis | 1 | 2010 | 7 | 0.020 |
Why?
|
| Allergens | 1 | 2010 | 10 | 0.020 |
Why?
|
| Epinephrine | 1 | 2010 | 37 | 0.020 |
Why?
|
| Hyperlipidemias | 1 | 2010 | 38 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 237 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 79 | 0.020 |
Why?
|
| Alleles | 1 | 2010 | 358 | 0.020 |
Why?
|
| Genotype | 1 | 2010 | 462 | 0.020 |
Why?
|
| Prevalence | 1 | 2010 | 526 | 0.020 |
Why?
|
| Incidence | 1 | 2010 | 581 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2010 | 2662 | 0.010 |
Why?
|